324 related articles for article (PubMed ID: 18565293)
21. [Biological treatment options for Graves' ophthalmopathy].
El Fassi D; Nielsen CH; Hegedüs L
Ugeskr Laeger; 2008 Jun; 170(24):2128-30. PubMed ID: 18565294
[TBL] [Abstract][Full Text] [Related]
22. A review of biologic treatments for psoriasis with emphasis on infliximab.
Pirzada S; Tomi Z; Gulliver W
Skin Therapy Lett; 2007 Apr; 12(3):1-4. PubMed ID: 17487347
[TBL] [Abstract][Full Text] [Related]
23. Pyoderma gangrenosum and tumor necrosis factor α agents.
Rallis E; Koumantaki-Mathioudaki E; Tsiatoura A; Stavropoulos P; Katsambas A
Cutis; 2013 Oct; 92(4):E1-2. PubMed ID: 24195097
[No Abstract] [Full Text] [Related]
24. Biologic therapies for psoriasis. A systematic review.
Boehncke WH; Prinz J; Gottlieb AB
J Rheumatol; 2006 Jul; 33(7):1447-51. PubMed ID: 16724367
[TBL] [Abstract][Full Text] [Related]
25. Impact of TNF-α antagonists on the quality of life in selected skin diseases.
Gisondi P; Girolomoni G
G Ital Dermatol Venereol; 2013 Jun; 148(3):243-8. PubMed ID: 23670060
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapies in dermatologic disorders.
Fallen RS; Terpstra CR; Lima HC
Med Clin North Am; 2012 May; 96(3):565-82, x-xi. PubMed ID: 22703856
[TBL] [Abstract][Full Text] [Related]
27. Update on the mechanisms and efficacy of biological therapies for psoriasis.
Koo J; Khera P
J Dermatol Sci; 2005 May; 38(2):75-87. PubMed ID: 15862940
[TBL] [Abstract][Full Text] [Related]
28. Pyoderma gangrenosum in a patient with primary cutaneous peripheral T-cell lymphoma, not otherwise specified.
Patsatsi A; Koletsa T; Sotiriadis D; Kartsios C; Papaconstantinou A; Kostopoulos I
Eur J Dermatol; 2012; 22(6):792-3. PubMed ID: 23228951
[No Abstract] [Full Text] [Related]
29. A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 2.
Bremmer M; Deng A; Gaspari AA
Dermatitis; 2009; 20(5):243-56. PubMed ID: 19807998
[TBL] [Abstract][Full Text] [Related]
30. Erythrodermic psoriasis: current and future role of biologicals.
Stinco G; Errichetti E
BioDrugs; 2015 Apr; 29(2):91-101. PubMed ID: 25752640
[TBL] [Abstract][Full Text] [Related]
31. Biologic survival.
Noiles K; Vender R
J Drugs Dermatol; 2009 Apr; 8(4):329-33. PubMed ID: 19363851
[TBL] [Abstract][Full Text] [Related]
32. [Biological treatment of psoriasis and psoriatic arthritis].
Kragballe K; Deleuran B
Ugeskr Laeger; 2008 Jun; 170(24):2148-50. PubMed ID: 18565300
[TBL] [Abstract][Full Text] [Related]
33. Factors associated with the prescription of "traditional" or "biological" systemic treatment in psoriasis.
Tabolli S; Paradisi A; Giannantoni P; Gubinelli E; Abeni D
J Dermatolog Treat; 2015 Feb; 26(1):37-40. PubMed ID: 24559128
[TBL] [Abstract][Full Text] [Related]
34. Adalimumab vs. etanercept in psoriasis.
Downs AM
Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
[No Abstract] [Full Text] [Related]
35. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
Bos WE; Thio HB; Neumann HA; van der Fits L; Prens EP
Ned Tijdschr Geneeskd; 2006 May; 150(19):1065-70. PubMed ID: 16733982
[TBL] [Abstract][Full Text] [Related]
36. The Role of Biologic Therapies in Dermatology.
Fathi R; Armstrong AW
Med Clin North Am; 2015 Nov; 99(6):1183-94. PubMed ID: 26476247
[TBL] [Abstract][Full Text] [Related]
37. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
[TBL] [Abstract][Full Text] [Related]
38. [Biological therapy treatment of juvenile idiopathic arthritis].
Herlin T
Ugeskr Laeger; 2008 Jun; 170(24):2105-8. PubMed ID: 18565289
[TBL] [Abstract][Full Text] [Related]
39. Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: a case series.
Bhutani T; Koo J
J Dermatolog Treat; 2011 Apr; 22(2):75-8. PubMed ID: 20524874
[TBL] [Abstract][Full Text] [Related]
40. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
